Welcome to our dedicated page for PFIZER SEC filings (Ticker: PFE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PFIZER's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PFIZER's regulatory disclosures and financial reporting.
Pfizer Inc. President, R&D Christoffel Boshoff had 816 shares of common stock withheld on February 23, 2026 to cover tax obligations upon the vesting of restricted stock units, at a price of $27.06 per share. After this tax-withholding disposition, he directly holds 154,829 shares and indirectly holds 709 shares through a Rule 16b-3 plan.
Pfizer Inc. senior vice president and controller Jennifer B. Damico reported a tax-related share disposition. On the vesting of restricted stock units, 419 shares of common stock were withheld at $27.06 per share to satisfy tax obligations, leaving her with 12,186 directly held shares.
Pfizer Inc. Chairman and CEO Albert Bourla reported an acquisition of derivative securities linked to Pfizer common stock. On 02/12/2026, he received 2,883 Phantom Stock Units SSP at $27.47 per unit under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
Each unit represents one phantom share of common stock and is settled in cash after his separation from service. Following this grant, Bourla beneficially owned 757,286 derivative units on a direct basis, providing additional deferred, cash-settled exposure to Pfizer’s share value rather than immediate stock ownership.
Pfizer Inc filed a Form 13F reporting its institutional holdings. The report lists 21 securities entries with a total reported market value of $236,464,562 as shown on the Form 13F summary page. The filing was signed by Madelyn D. Purcell, Assistant General Counsel on 02-10-2026.
Pfizer Inc. filed a current report to make investors aware that it has released its financial results for the fourth quarter of 2025. The company did this by issuing a press release on February 3, 2026, which is attached to the report as Exhibit 99.
The press release is formally provided for information purposes and is not treated as being legally “filed” under certain securities law provisions. The filing also includes an Inline XBRL cover page data file as Exhibit 104.
Pfizer Inc. executive Christoffel Boshoff reported a tax‑related share withholding tied to equity compensation. On January 30, 2026, 12,887 shares of Pfizer common stock were withheld at $26.44 per share to satisfy tax obligations upon vesting of restricted stock units, rather than being an open‑market sale. After this transaction, Boshoff beneficially owned 155,645 shares directly and 698 shares indirectly through a Rule 16b‑3 plan.
Pfizer Inc. Chairman and CEO Albert Bourla reported an acquisition of 79 Phantom Stock Units SSP on January 14, 2026 at $25.58 per unit. Each unit represents one phantom share of Pfizer common stock and is part of the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. After this transaction, Bourla held 743,136 phantom stock units. These units are settled in cash after his separation from service and can be moved into an alternative investment account at any time, so they function as deferred cash-based compensation rather than actual shares.
Pfizer Inc. director Mortimer J. Buckley reported a deferred compensation transaction involving phantom stock units tied to Pfizer common stock. On 12/31/2025, he acquired 1,506.024 phantom stock units, each representing one phantom share of common stock. These units reflect deferred director compensation, including dividend equivalents, and are designed to be settled in cash or Pfizer common stock at the director’s election after he retires from the Board of Directors. Following this transaction, Buckley beneficially owned a total of 15,078.063 phantom stock units, all held as a direct interest.
Pfizer Inc. director reports additional deferred compensation units
A Pfizer Inc. director reported acquiring 1,857.43 phantom stock units linked to Pfizer common stock on 12/31/2025. Each unit represents one phantom share of common stock. After this transaction, the director beneficially owns 149,314.146 derivative securities in the form of phantom stock units.
These units represent deferred director compensation, including dividend equivalents, that will be settled in either cash or Pfizer common stock at the director’s election after retirement from the Board of Directors.
Pfizer Inc director Shantanu Narayen reported acquiring 2,008.032 phantom stock units on Pfizer common stock as of 12/31/2025. Each unit represents one phantom share of common stock tied to deferred director compensation, including dividend equivalents.
These units are to be settled in cash or common stock at the director's election after retirement from the Board of Directors. Following this transaction, Narayen beneficially owned 183,164.359 derivative securities related to Pfizer common stock, recorded at a derivative security price of $24.9.